Switch from cyclosporine A to mycophenolate mofetil in nephrotic children

• Published in: Pediatric nephrology (Berlin, West) Vol. 20; no. 4; pp. 482 - 485
• Main Authors: Ulinski, Tim, Dubourg, Laurence, Saïd, Marie Hélène, Parchoux, Bernadette, Ranchin, Bruno, Cochat, Pierre
• Format: Journal Article
• Language: English
• Published: Germany Springer Nature B.V 01-04-2005
• Subjects: Adolescent; Blood pressure; Child; Child, Preschool; Cyclosporine - adverse effects; Cyclosporine - therapeutic use; Disease control; Drug dosages; Female; Gingival Hypertrophy - chemically induced; Glomerular Filtration Rate - drug effects; Hematology; Humans; Hypertrichosis - chemically induced; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Kidney - drug effects; Kidney diseases; Male; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Nephrotic Syndrome - drug therapy; Nephrotic Syndrome - physiopathology; Patients; Remission (Medicine); Retreatment; Statistical significance; Steroids; Treatment Outcome
• ISSN: 0931-041X; 1432-198X
• DOI: 10.1007/s00467-004-1778-4

Nephrotoxicity is a well-known adverse effect of cyclosporine A (CyA) treatment in children with steroid-dependent (SD) and steroid-resistant (SR) nephrotic syndrome (NS). We analyzed nine children (age: 3.3-15.7 years, two girls) with SD or SR NS who experienced a significant decrease in their GFR under CyA treatment as measured by inulin clearance (C(IN)). Mycophenolate mofetil (MMF) was introduced progressively until doses of 1 g/1.73 m(2) twice daily were reached. CyA treatment was stopped after introduction of MMF and oral steroids were reduced if possible. After a median follow up of 261 days, no adverse effects of MMF such as diarrhea or hematological anomalies occurred in our patients. After switching from CyA to MMF, those children with SD NS remained in remission without proteinuria and those with SR NS did not show any significant changes in their residual proteinuria. The serum protein level did not change significantly in any of the children analyzed. GFR increased from a mean of 76.9+/-4.8 to 119.9+/-5.9 mL/1.73 m(2) per min (P<0.001). Oral steroid treatment could be reduced from a median [range] prednisone dose of 0.85 [0.26-2.94] mg/kg/d pre-MMF to 0.29 [0-1.1] mg/kg per day (P=0.026), and blood pressure decreased moderately after CyA withdrawal, but the difference did not reach statistical significance. We conclude that a switch from CyA to MMF seems to be safe for children with SDNS and SRNS in terms of side effects as well as disease control, at least in the short term. Interruption of CyA treatment lead to rapid amelioration of kidney function in these children, often associated with steroid sparing, which may lead to additional benefit for growth velocity, blood pressure and physical appearance.